Identification of a novel non-ATP-competitive protein kinase inhibitor of PGK1 from marine nature products.

Yuying Wang, Lulu Sun, Guihong Yu, Xin Qi, Aotong Zhang, Zhimin Lu, Dehai Li, Jing Li

Biochemical pharmacology 2021 Jan

filter terms:

Phosphoglycerate kinase 1 (PGK1) acts as both a glycolytic enzyme and a protein kinase playing critical roles in cancer progression, thereby being regarded as an attractive therapeutic target for cancer treatment. However, no effective inhibitor of PGK1 has been reported. Here, we demonstrate that GQQ-792, a thiodiketopiperazine derivative from marine nature products, is a non-ATP-competitive inhibitor of PGK1 with the disulfide group within the structure of GQQ-792 as a key pharmacophore. The disulfide group of GQQ-792 binds to Cys379 and Cys380 of PGK1, resulting in occlusion of ATP from binding to PGK1. GQQ-792 treatment blocks hypoxic condition- and EGF stimulation-enhanced protein kinase activity of PGK1 that phosphorylates PDHK1 at T338 in glioblastoma cells; this treatment leads to decreased lactate production and glucose uptake, and subsequent apoptosis of glioblastoma cells. Animal studies reveal that GQQ-792 significantly inhibits the growth of tumor derived from glioblastoma cells. These findings underscore the potential of GQQ-792 as a promising anticancer agent and pave an avenue to further optimize the structure of GQQ-792 basing on its target molecule and pharmacophore in future. Copyright © 2020 Elsevier Inc. All rights reserved.

Citation

Yuying Wang, Lulu Sun, Guihong Yu, Xin Qi, Aotong Zhang, Zhimin Lu, Dehai Li, Jing Li. Identification of a novel non-ATP-competitive protein kinase inhibitor of PGK1 from marine nature products. Biochemical pharmacology. 2021 Jan;183:114343